WHO names 2027 Southern Hemisphere flu strains; vaccines come later
The World Health Organization has named the influenza viruses it recommends for vaccines used in the 2027 Southern Hemisphere season. The September 25 recommendation is an early decision in vaccine production. It does not mean a 2027 product has been licensed, released, or shown to be effective against viruses that will circulate next year.
Comparing WHO's 2026 recommendation with the new one shows the actual change. The A(H1N1)pdm09 reference remains A/Missouri/11/2025-like. Both the A(H3N2) and B/Victoria references change. For egg-based vaccines, WHO now calls for A/Darwin/1454/2025-like and B/Tokyo/EIS13-175/2025-like viruses. For cell culture, recombinant-protein, or nucleic-acid vaccines, it calls for A/Darwin/1415/2025-like and B/Pennsylvania/14/2025-like viruses. These names identify reference viruses for two manufacturing routes; they do not identify separate flu seasons or make one route inherently superior.
WHO makes these choices after reviewing global surveillance and virus characterization. The recommendation describes strains intended to match likely circulation. It cannot establish in September 2026 which strains will dominate in 2027, how closely a manufactured vaccine will match them, or how much protection a particular person will have. It also concerns the Southern Hemisphere 2027 season, not a replacement for vaccines being used in the current 2026 season or for the Northern Hemisphere's 2026–27 season.
A recommendation is not a vial
National review and production remain distinct steps. Australia's Therapeutic Goods Administration (TGA) provides a concrete example from the 2026 Southern Hemisphere season: it processed 65 batch-release requests, reviewed manufacturers' protocols and results for all 65, and conducted its own potency tests on a selection of inactivated-vaccine batches. Those are 2026 results, not evidence that 2027 batches already exist. New Zealand's Medsafe regulatory account likewise separates international composition recommendations from national formulation approval.
For health systems, the near-term news is a production target. Manufacturers can work from the named reference viruses; regulators can assess the products and batches that follow. Readers deciding about vaccination now should use current local guidance, because the WHO's 2027 recipe does not change the availability or approval status of today's vaccines.